Recent studies have suggested that a short course of antibiotics, compared to longer durations, are just as efficacious for many common infections. The appropriate duration of urinary tract infections for men, by definition complicated, is uncertain due to the risk of developing secondary prostatitis. A new study evaluates 7 vs 14 days of antibiotic treatment of UTIs in men without fever.

Redeem your CPE or CME credit here!

References and resources: Drekonja DM, Trautner B, Amundson C, Kuskowski M, Johnson JR. Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial. JAMA. 2021;326(4):324–331. doi:10.1001/jama.2021.9899

Continuing Education Information:
Learning Objectives:
1. Describe the potential complications of urinary tract infections in men that are different than women
2. Implement the findings of this study into a clinical practice

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-316-H01-P
Initial release date: 9/14/21
Expiration date: 9/14/22
Complete CPE & CME details can be found here!

Follow CEimpact on Social Media:
LinkedIn
Instagram

The United States Preventative Services Task Force (USPSTF) announced new recommendations for diabetes screening. Approximately 34.5% of the US population has pre-diabetes – frequently attributed to the 75% of US adults with an overweight or obese body mass index. What makes 35 years old the new test screening age for diabetes compared to 40?

Guest:
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad

Redeem your CPE or CME credit here!

References and resources: US Preventive Services Task Force. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(8):736–743. doi:10.1001/jama.2021.12531

Continuing Education Information:
Learning Objectives:
1. Identify individuals who should be screened for diabetes
2. Describe the role of racial and ethnic disparities in diabetes

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-323-H01-P
Initial release date: 9/07/21
Expiration date: 9/07/22
John A. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here

Follow CEimpact on Social Media:
LinkedIn
Instagram

Proton Pump Inhibitors (PPIs), like all drugs, cause adverse drug events. Given the sheer number of patients prescribed, or using over-the-counter, PPIs, many practitioners may question continued use. Hear as Geoff examines a recent study from Ann Arbor which looked at the effects of a deprescribing program to step down from PPIs.

Redeem your CPE or CME credit here by getting a GameChangers Subscription!

References and resources:
N/A

Continuing Education Information:
Learning Objectives:
1. Discuss a recent study evaluating the risks of proton pump inhibitors
2. Identify potential patients that could benefit from proton pump inhibitor discontinuation

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-232-H01-P
Initial release date: 8/10/21
Expiration date: 8/10/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The Delta variant has made it clear the COVID pandemic is far from over. Recent studies have suggested that immunocompromised patients may have a reduced or no antibody response to the currently available COVID-19 vaccines. On August 13th, the CDC and FDA recommended that patients receive an additional vaccination. Hear Dr. Geoff Wall and guest, Dr. Nicole Alvey, on how immunocompromised patients need an additional dose, and how to prioritize their care. Drs. Wall and Alvey also share preliminary thoughts on booster vaccines based on the U.S. Surgeon General’s announcement on 8.18.21 recommending booster shots available at 8 months; however, the Biden administration announced on 8.25.21 that booster shots should be available after 6 months of the last dose, pending ACIP review.

Guest:
Nicole Alvey, PharmD, BCPS, FAST
Associate Professor, Roosevelt University

Earn CME or CPE credit with a GameChangers Subscription!

Want more? Head over to The Pharmacy Network to watch our Expert in Residence discuss all things COVID-19 boosters + additional shots titled All About Boosters.

References and resources:

Continuing Education Information:
Learning Objectives:
1. Describe risk factors for having a poor antibody response to currently available COVID-19 vaccines
2. Implement new recommendations for an additional vaccination of COVID-19 in eligible patients

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-XXX-H06-P
Initial release date: 8/24/21
Expiration date: 9/7/22
Dr. Alvey reports no actual or potential conflicts of interest associated with this activity.
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

A landmark paper published in 2002 set the standard for Targeted Temperature Management (TTM)  by having hospitals use TTM protocols to "cool" patients for a period of time after cardiac arrest to improve neurologic outcomes. On June 17th, 2021, the TTM-2 study was published and changed this standard. What is the future of the TTM modality in cardiac arrest patients?

Redeem your CPE or CME credit here!

References and resources:
Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. N Engl J Med. 2021 Jun 17;384(24):2283-2294. doi: 10.1056/NEJMoa2100591. PMID: 34133859.

Continuing Education Information:
Learning Objectives:
1. Describe the TTM-2 study
2. Discuss the theoretical benefits of maintaining a normal or low body temperature immediately following cardiac arrest.

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-263-H01-P
Initial release date: 8/17/21
Expiration date: 8/17/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Do psychedelics treat mental illness? In this GameChanger episode host, Geoff Wall and guest, Sarah Grady, a psychiatric pharmacist, discuss a recent NEJM article comparing psilocybin (magic mushrooms) to escitalopram.

Guest:
Sarah Grady, PharmD
Drake University

Redeem your CPE or CME credit here with your GameChangers Subscription!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964


References and resources:
Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. PMID: 33852780.

Continuing Education Information:
Learning Objectives:
1. Discuss a recent study comparing psilocybin to escitalopram in depression
2. Identify potential patients that could benefit from psilocybin based on the study

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-231-H01-P
Initial release date: 8/3/21
Expiration date: 8/3/22
Dr. Sarah Grady reports no actual or potential conflicts of interest associated with this activity.
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The delta variant of COVID-19 has put the US in the precarious position of a fourth wave of the disease -- how efficacious are our vaccines against this variant? Also, are any new treatments for early COVID-19 being studied to help continue the fight? Find out more in this episode!

Redeem your CPE or CME credit here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 Jul 22;385(4):320-329. doi: 10.1056/NEJMoa2107058. Epub 2021 Jun 30. PMID: 34192428; PMCID: PMC8262622.

Rossignol J, Matthew C, Oaks J, et al. Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization. medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441

Continuing Education Information:
Learning Objectives:
1. Discuss the differences in effectiveness between the mRNA and adenovirus vaccines for the delta variant of COVID-19
2. Describe the use of nitazoxanide in mild to moderate COVID-19 and barriers to its use

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-XXX-H01-P
Initial release date: 8/31/21
Expiration date: 8/24/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

The first new treatment for Alzheimer's, aducanumab, was approved by the Food and Drug Administration on June 7, 2021. This approval did not come without controversy. Learn what the available data show for efficacy and safety and whether or not the current list price of $56,000 per year meets cost-effectiveness thresholds.

Guest
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad

Redeem your CPE or CME credit here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Aducanumab for Alzheimer's Disease: Effectiveness and Value. Institute for Clinical and Economic Review. June 30, 2021. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Revised_Evidence_Report_06302021.pdf

Continuing Education Information:
Learning Objectives:
1. Discuss the outcomes for phase III trials of aducanumab
2. Define the cost-effectiveness of aducanumab

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-265-H01-P
Initial release date: 7/27/21
Expiration date: 7/27/22
John A. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

A new study evaluates the cost-effectiveness of dapagliflozin in heart failure. Geoff and Jake continue the conversation from "Home Sweet Home (It's Where the Heart Is)" [Previous Episode] about the role of SGLT-2is in heart failure. This time the conversation is focused on the cost-effectiveness and QALYs. Is the price right for improved care?

Redeem your CPE or CME credit here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. Published online May 26, 2021. doi:10.1001/jamacardio.2021.1437

Continuing Education Information:
Learning Objectives:
1. Define QALY
2. Discuss the cost-effectiveness of dapagliflozin in heart failure

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-264-H01-P
Initial release date: 7/20/21
Expiration date: 7/20/2022
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

New asthma guidelines came out in 2020, yet the answer to triple or dual inhaler therapy wasn't explicitly answered. In this episode host, Geoff Wall and guest, Jake Galdo discuss the role of triple inhaler (ICS-LABA-LAMA) in the management of severe persistent and uncontrolled asthma.

Redeem your CPE or CME credit with a GameChangers Subscription here!

We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. JAMA. 2021 May 19:e217872. doi: 10.1001/jama.2021.7872. Epub ahead of print. PMID: 34009257; PMCID: PMC8135065.

Continuing Education Information:
Learning Objectives:
1. Discuss a recent study comparing triple to dual inhaler therapy in asthma
2. Describe the adverse drug events associated with triple inhaler therapy in asthma
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-230-H01-P
Initial release date: 7/13/21
Expiration date: 7/13/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram